March 2018

Cover of the current issue of ASBMB Today

Mystery: myalgic encephalomyelitis

Q&A with Ursula Jakob of UMich

Recognizing JBC first authors


  • The ASBMB's Interactive Mentoring Activities for Grantsmanship Enhancement (IMAGE) grant-writing workshop is for assistant professors and postdocs who are transitioning into independent faculty positions. The deadline to apply is April 13. Learn more  


ASBMB Today March 2018

This month, we look at myalgic encephalomyelitis, aka chronic fatigue syndrome; the NIH recently announced $7 million in designated funding, but advocates say that’s nowhere near enough. JBC associate editor Ursula Jakob discusses her work with bacterial bleach. And we introduce the 2018 JBC/Herbert Tabor Young Investigator Award winners.   

Call for judges at the 22nd Undergraduate Poster Competition

Volunteers are needed to assist in the undergrad poster contest at the 2018 ASBMB Annual Meeting  on  April 21. Learn about eligibility requirements and register by  Feb. 13. 

Journal News

The Year in JBC

Look back on 2017 with The Year in JBC, a special collection of papers across the journal's subject areas. And catch up on review papers you may have missed with the  2017 Minireview Compendium . Both of the collections are free to download. Share them with your peers and students.

Your technological advances belong at MCP

Molecular & Cellular Proteomics  is the home for papers describing new, impactful technologies that make substantial contributions to the understanding of proteomics. As described in the editors'  January editorial, papers describing these technologies do not have to include solutions to biological problems. The editors encourage authors to submit technology papers to MCP.

Member News

Jakob joins JBC as associate editor

Ursula Jakob of the University of Michigan became an associate editor for the Journal of Biological Chemistry in September. She spoke with ASBMB Today about her lab’s work exploring molecular chaperones and mechanisms of bleach resistance in bacterial and human cells.

Cech named science adviser to STORM Therapeutics

STORM Therapeutics has named Thomas Cech as a science adviser. Founded in 2015, STORM Therapeutics is a British-based developer of small-molecule inhibitors of RNA-modifying enzymes for the treatment of cancer. A leading figure in the field of RNA research, Cech shared the 1989 Nobel Prize in chemistry for discovering the catalytic properties of RNA.

» See All News Stories

ASBMB Journals JBC Cover MCP Cover JLR Cover

Lipid Corner